NASDAQ:CODX - Co-Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.18 +0.03 (+2.61 %)
(As of 03/18/2019 04:00 PM ET)
Previous Close$1.15
Today's Range$1.18 - $1.19
52-Week Range$0.90 - $6.66
Volume1,100 shs
Average Volume1.05 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
CUSIPN/A
Phone+1-801-2789769

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
Next Earnings DateN/A
OptionableNot Optionable

Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

What price target have analysts set for CODX?

1 brokers have issued 1-year price objectives for Co-Diagnostics' shares. Their forecasts range from $2.00 to $2.00. On average, they expect Co-Diagnostics' share price to reach $2.00 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Co-Diagnostics.

What is the consensus analysts' recommendation for Co-Diagnostics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics.

Has Co-Diagnostics been receiving favorable news coverage?

Media headlines about CODX stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Co-Diagnostics earned a news impact score of 1.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the folowing people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)
  • Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)
  • Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $1.18.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is http://codiagnostics.com/.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 4049 S Highland Dr, SALT LAKE CITY, UT 84124-1664, United States. The company can be reached via phone at +1-801-2789769.


MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel